Mostrar el registro sencillo del ítem

dc.contributor.author
Renna, Nicolas Federico  
dc.contributor.author
Diez, Emiliano Raúl  
dc.contributor.author
Miatello, Roberto Miguel  
dc.date.available
2019-07-16T18:57:19Z  
dc.date.issued
2014-09  
dc.identifier.citation
Renna, Nicolas Federico; Diez, Emiliano Raúl; Miatello, Roberto Miguel; Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model; Public Library of Science; Plos One; 9; 9; 9-2014; 1-8  
dc.identifier.issn
1932-6203  
dc.identifier.uri
http://hdl.handle.net/11336/79662  
dc.description.abstract
Background In this study, we used vidagliptin(V) to examine the role of the DDP-IV, incretin system component, in the activation of different molecular inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment that supports cardiovascular remodeling. Methods Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+V: (5 mg/kg per day for 6 weeks) (n = 8 each group). Metabolic variables and systolic blood pressure were measured. The TBRAS, eNOS activity, and NAD(P)H oxidase activity were estimated to evaluate oxidative stress. Cardiac and vascular remodeling were evaluated. To assess the cytokine, NF-kB and VCAM-1 immunostaining techniques were used. Results The FFHR experimental model presents metabolic syndrome criteria, vascular and cardiac remodeling, vascular inflammation due to increased expression of NF-kB, VCAM-1, and pro-atherogenic cytokines. Chronic treatment with V was able to reverse total or partiality of variables studied. Conclusions Data demonstrated an important effect of DDP-IV in reducing vascular inflammation, accompanied by a favorable reduction in metabolic and structural parameters.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Public Library of Science  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Vidagliptin  
dc.subject
Cytokins  
dc.subject
Metabolic Syndrome  
dc.subject
Hypertension  
dc.subject.classification
Fisiología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2019-06-11T15:15:47Z  
dc.journal.volume
9  
dc.journal.number
9  
dc.journal.pagination
1-8  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
San Francisco  
dc.description.fil
Fil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Fisiología Patológica; Argentina  
dc.description.fil
Fil: Diez, Emiliano Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina  
dc.description.fil
Fil: Miatello, Roberto Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Fisiología Patológica; Argentina  
dc.journal.title
Plos One  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1371/journal.pone.0106563  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106563